PEPG news

Latest 2 stories · newest Aug 6, 2026

PEPG

PepGen reports Q2 2026 results, DSMB recommends dosing escalation.

Biotech company PepGen reported financial results affirming long-term solvency. It announced positive breakthroughs in its DM1 trial, including a Data Safety Monitoring Board's recommendation to escalate dosing due to the drug's promising safety profile.

Earnings Aug 6, 2026 sentiment +0.50 SEC filing ↗

PEPG

PepGen presents EDO platform data for DM1 candidate PGN-EDODM1

PepGen Inc. released a May 2026 company presentation detailing clinical progress of its oligonucleotide therapy PGN-EDODM1 for myotonic dystrophy type 1, highlighting dose-dependent splicing correction from FREEDOM and FREEDOM2 trials. The company faces ongoing regulatory interactions including a pa…

Regulatory May 21, 2026 sentiment -0.15 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same PEPG feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/PEPG/newsSTART FREE